The central problem these platforms address is the tumor microenvironment, the dynamic and immunosuppressive niche that governs cancer progression, immune evasion, and therapeutic resistance. Tumors are not merely masses of malignant cells; they are complex ecosystems containing cancer stem cells, stromal cells such as fibroblasts and endothelial cells, angiogenic vessels, extracellular matrix, signaling molecules, and a diverse cast of immune populations including macrophages, dendritic cells, neutrophils, natural killer cells, B cells, and T cells. Within this milieu, regulatory T cells, myeloid-derived suppressor cells, and elevated checkpoint molecules conspire to blunt anti-tumor immunity. The review frames tumor–immune dynamics through the cancer immunoediting framework of elimination, equilibrium, and escape, emphasizing that immune evasion during the escape phase is what allows clinically detectable malignancy to emerge and that the microenvironment is an active driver of tumor evolution and therapeutic resistance rather than a passive backdrop.

Immunosuppression within the tumor microenvironment operates through multiple mechanistic layers. An immunosuppressive cytokine milieu dominated by TGF-β, IL-10, and IL-6 suppresses T cell activation while promoting the expansion of myeloid-derived suppressor cells and M2-polarized macrophages. Chemokine gradients, including CCL22 and the CXCR4/CXCL12 axis, actively recruit suppressive cell populations to the tumor site while excluding cytotoxic effector cells, creating spatially organized immunosuppressive niches that shield tumor cells from immune destruction. Tumor-associated macrophages, among the most abundant and plastic immune populations in the microenvironment, are typically driven toward a pro-tumorigenic M2 phenotype through IL-4, IL-13, and IL-10 signaling, converting a potentially anti-tumor force into an active promoter of progression and therapy resistance. Tumors are further classified as inflamed or hot, immune-excluded, or immune-desert or cold, with the latter two categories being largely refractory to immunotherapy, a reality that underscores why models preserving spatial and stromal complexity are so valuable.

At the heart of immune evasion lies the exploitation of checkpoint pathways. PD-L1 on tumor cells engages PD-1 on T cells, inducing a state of exhaustion characterized by reduced proliferation, cytokine production, and cytotoxicity, while CTLA-4 dampens T cell priming by competing with CD28 for B7 ligands. Emerging checkpoints including LAG-3, TIM-3, and TIGIT further contribute to intratumoral T cell exhaustion and represent targets for next-generation immunotherapy. Immune checkpoint inhibitors have demonstrated efficacy across a remarkable range of malignancies, including non-small cell lung cancer, urothelial bladder cancer, head and neck squamous cell carcinoma, breast cancer, cutaneous squamous cell cancer, melanoma, renal cell cancer, and Hodgkin’s lymphoma. Yet predicting which patients will benefit remains difficult, which is precisely where co-culture platforms that preserve viable immune cells alongside living tumor tissue promise to change clinical practice.

The review traces the evolution of cancer models from flat two-dimensional monolayers, which advanced early understanding of tumor biology but fail to capture complex tumor–microenvironment interactions, to three-dimensional systems that more accurately recapitulate in vivo tumor structure and behavior. Gene expression profiling of three-dimensional multicellular tumor spheroids has revealed upregulation of hypoxia-responsive genes and downregulation of cell cycle-related genes compared to two-dimensional models, and enhanced mevalonate pathway activity has been observed in quiescent spheroid cells, underscoring the context-dependent nature of anticancer responses in 3D. Spheroids, typically 200 to 500 micrometers in diameter, form through integrin- and cadherin-mediated self-assembly and can be generated by pellet culture, hanging drop, liquid overlay, or spinner techniques, each with distinct trade-offs in scalability, monitoring, and hypoxic core formation. When co-cultured with immune cells such as PBMCs, spheroids enable modeling of tumor–immune interactions and intratumoral heterogeneity, making them a valuable preclinical research tool.

Organoids, often described as mini-organs, go further by self-organizing to recapitulate native tissue architecture and function through lineage commitment and spatial cell sorting guided by extracellular matrix and culture medium cues. Patient-derived tumor organoids have now been generated across colorectal, pancreatic, breast, lung, and brain cancers, among others, retaining the mutational profiles, histopathology, and cellular diversity of the source tumor. Matrigel-based systems remain the most widely used due to accessibility and standardized workflows, despite batch-to-batch variability, while bioengineered synthetic matrices offer tunable stiffness and improved reproducibility at higher cost. Advanced technologies are pushing the field further: microfluidic organ-on-a-chip systems enable perfused, vascularized organoids modeling fluid flow and immune infiltration; air–liquid interface culture preserves epithelial, stromal, and immune components with improved oxygenation; and microwell arrays, droplet encapsulation, and acoustic aggregation enable high-throughput, size-controlled production, though typically limited to short-term culture.

The translational centerpiece of the review is the PDTO–PBMC co-culture system, which the authors describe as enabling reconstitution of autologous immune responses in an antigen-agnostic manner. The landmark study by Dijkstra and colleagues established that co-culturing peripheral blood lymphocytes with tumor organoids expands CD8-positive T cells that kill tumor organoids but spare healthy tissue-derived organoids, with killing efficiency of 20 to 80 percent depending on tumor type, and confirmed antigen-specificity through HLA-blocking experiments. The review is careful to define what constitutes genuine functional immune reconstitution rather than mere physical co-localization: HLA-dependent tumor-selective killing, CD137 upregulation as a marker of tumor-reactive T cell activation, interferon-gamma secretion, and granzyme B-mediated cytotoxicity must all be demonstrated. Checkpoint blockade responsiveness has been validated in immune-enhanced organoid platforms, with anti-PD-1 treatment increasing CD3-positive and CD8-positive T cell recruitment, and air–liquid interface models showing organoid responses to PD-1/PD-L1 blockade correlating with clinical outcomes in approximately 85 percent of cases.

Beyond T cells, the platforms extend across the immune repertoire. Cancer-associated fibroblasts co-cultured with organoids enhance tumor growth, promote epithelial–mesenchymal transition, and confer therapy resistance across colorectal, pancreatic, hepatocellular, and esophageal cancers, while endothelial co-culture illuminates tumor-induced angiogenesis and vascular niche-dependent drug resistance. Macrophage co-cultures reveal that sirtuin-1 promotes M2 polarization and suppresses CD8-positive T cell activity in colorectal cancer, and that the CCL5–Sp1–AREG axis mediates tumor–macrophage crosstalk in pancreatic cancer. Dendritic cell co-cultures expose tolerogenic shifts in tumor microenvironments, and natural killer cell studies in breast and pancreatic cancer models have demonstrated both therapeutic potential and tumor-induced immune impairment. CAR T cell evaluation has been particularly transformative: patient-derived bladder cancer organoids have been validated as reliable preclinical platforms for CAR T testing, neuroblastoma organoids have modeled CAR T infiltration and antigen loss, and glioblastoma organoids now serve as real-time avatars for assessing responses to clinical CAR T cell therapy.

The review does not shy away from sobering limitations. Most published work remains at the proof-of-concept stage, with prospective clinical validation data still sparse and no defined response thresholds for what magnitude of in vitro cytotoxicity reliably predicts clinical benefit. Organoid establishment success rates vary dramatically, from 22 percent rising to 75 percent with optimized protocols in metastatic colorectal cancer, 58 percent in pancreatic cancer, and as low as 17 percent for conventional lung cancer protocols versus over 90 percent with optimized free-floating platforms. PBMC viability after cryopreservation, delays exceeding 24 hours between blood collection and processing, and inter-patient immune repertoire variation all confound outcomes. Turnaround from biopsy to functional readout typically spans three to six weeks, though accelerated platforms have demonstrated feasibility within 7 to 14 days. Clonal evolution poses a further threat, as culture-adapted subclones may displace clinically relevant immune-evasive populations, and therapy-induced changes can alter neoantigen repertoires and checkpoint expression. The authors call for the newly proposed Minimum Information about Organoid Research reporting standard, reference organoid lines, external quality control programs, and a structured evidentiary roadmap toward companion diagnostic status under FDA and EU IVDR frameworks.

Looking forward, the convergence of microfluidics, spatial transcriptomics, single-cell multi-omics, and artificial intelligence promises to expand both the biological fidelity and translational utility of these platforms. Three-dimensional bioprinting allows spatially controlled deposition of tumor, immune, and stromal components that better recapitulate immune exclusion zones and stromal barriers, while machine learning applied to high-dimensional co-culture datasets holds promise for predicting patient-specific immunotherapy responses. The authors conclude that clinical validation of tumor–immune co-culture systems will be fundamental to achieving truly personalized cancer immunotherapy, in which each patient’s tumor is prospectively tested against their own immune cells to guide individualized treatment decisions, transforming organoid co-culture from a research curiosity into a functional companion diagnostic for precision oncology.

Subject of Research: Patient-derived tumor organoid co-culture systems for modeling tumor–immune interactions and evaluating cancer immunotherapy and precision oncology

Article Title: Patient-derived tumor organoid co-culture systems as translational platforms for cancer immunotherapy and precision oncology

Article References: Gadelkarim, M., Elsayed, A., Abaza, T., Bahr, A. R., Elsayed, Y., & Iqbal, O. (2026). Patient-derived tumor organoid co-culture systems as translational platforms for cancer immunotherapy and precision oncology. Clinical Cancer Bulletin, 5(1), Article 18. https://doi.org/10.1007/s44272-026-00067-1

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00067-1

Keywords: tumor organoids, co-culture, tumor microenvironment, cancer immunotherapy, immune checkpoint inhibitors, CAR T cells, PBMC, precision oncology, patient-derived models, adoptive cell therapy, organ-on-a-chip, companion diagnostics

The study, published Aug. 6 in Cell Reports Medicine, addresses one of the central challenges in oncology: two tumors that appear similar under a microscope can respond very differently to the same therapy. Breast cancer treatment decisions are increasingly guided by biomarkers, such as hormone-receptor status, HER2 amplification and DNA-repair alterations, but these measurements do not always reveal which drug will work best in a particular patient. The UCSF team investigated whether living tumor models could provide a functional test of treatment response alongside genomic and clinical information.

To create the organoids, researchers placed cells taken from patient tumors into a specialized gel engineered to support the biological conditions of the original cancer. Over several weeks, the cells organized into compact, three-dimensional structures containing hundreds or thousands of cells. Unlike conventional cancer cell lines grown as flat layers, organoids preserve aspects of tumor architecture and retain many of the molecular features found in the tissue from which they were derived. Their small size also makes it possible to expose large numbers of organoids to multiple drugs in parallel.

The team established a biobank of organoids from early-stage invasive breast cancers and compared their behavior with clinical information from patients enrolled in the I-SPY2 trial. I-SPY2 is designed to accelerate the testing of therapies for high-risk breast cancer by evaluating several treatments simultaneously in biologically defined patient groups. The trial has generated “response predictive subtypes,” molecular classifications intended to estimate how tumors will respond to therapies such as immunotherapy, platinum chemotherapy, PARP inhibitors and dual-HER2-targeted drugs.

Using these predictive subtypes and additional tumor biomarkers, the researchers built a computational framework to forecast how individual organoids would react to specific treatments. They then tested the predictions experimentally. The model was especially evaluated in organoids derived from triple-negative breast cancers, a subtype that lacks estrogen and progesterone receptors and does not show elevated levels of HER2. Because triple-negative tumors have fewer established molecular targets and can rapidly develop treatment resistance, patients are often treated with intensive chemotherapy, including platinum-based drugs.

One treatment combination examined in the study was veliparib plus platinum chemotherapy, referred to as VP. Veliparib inhibits PARP proteins, which help repair certain forms of DNA damage, while platinum drugs damage DNA directly. The combination is intended to overwhelm the tumor’s repair machinery, but not every triple-negative tumor is vulnerable to it. Among the organoids, the model identified one sample, designated TORG40, as having a particularly high likelihood of resistance. Laboratory experiments subsequently confirmed that TORG40 showed limited sensitivity to VP, providing a test of the prediction system.

The researchers then used TORG40 to conduct a high-throughput drug screen involving 386 small-molecule inhibitors. The screen highlighted ABT-263, a compound that targets proteins involved in cellular survival and can promote the removal of damaged or stressed cells. When ABT-263 was combined with cisplatin, a platinum chemotherapy drug, the treatment produced a markedly stronger effect against the resistant TORG40 organoid than either agent alone. The result suggests that functional drug screening may uncover vulnerabilities that are not obvious from standard biomarkers, although the combination remains an experimental finding rather than an established treatment.

The organoid experiments also identified HSP90 inhibitors as potential candidates for further study. HSP90 is a molecular chaperone that helps stabilize and maintain numerous proteins, including proteins involved in cancer growth and survival. Blocking HSP90 can disrupt several signaling pathways at once, which may be useful in tumors driven by complex or overlapping mechanisms. The researchers linked the organoid findings to a subset of I-SPY patients who appeared to respond more favorably to drugs in this class, offering an example of how laboratory observations can be connected back to clinical trial data.

The investigators emphasize that the organoids do not reproduce the full environment of a tumor inside the body. They lack blood vessels, immune cells, stromal tissue and the broader organ systems that influence how cancer cells receive signals and how drugs are distributed. The study also did not determine whether organoid-guided treatment decisions would improve patient outcomes over months or years. Even so, the findings support a “reverse translational” strategy in which clinical trial data are used to generate laboratory predictions, and organoid experiments are then used to discover and prioritize therapies. With further validation in prospective clinical studies, patient-derived organoids could eventually become a practical bridge between molecular biomarkers and more individualized breast cancer treatment.

Subject of Research: Lab-produced tissue samples

Article Title: Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer

News Publication Date: 6-Aug-2026

Web References: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00390-3

References: DOI: 10.1016/j.xcrm.2026.102973

Keywords: Breast cancer, triple-negative breast cancer, patient-derived organoids, tumor organoids, personalized medicine, biomarkers, drug resistance, combination therapy, cisplatin, veliparib, PARP inhibitors, HSP90 inhibitors, I-SPY2 trial, precision oncology

At the core of organoid technology lies the ability to cultivate miniature tumors from patient biopsy samples or pluripotent stem cells, preserving critical features such as genomic aberrations, cellular diversity, and tumor microenvironment components. This level of fidelity enables researchers to investigate cancer as a living ecosystem, where cellular interplay drives growth, metastasis, and resistance mechanisms. Reflecting the complexity of in vivo tumors, organoids have demonstrated remarkable reproducibility in predicting patient-specific drug sensitivity, a capability that has the potential to transform individualized treatment regimens and drastically reduce the trial-and-error approach in oncology.

The limitations inherent to conventional models have been a significant bottleneck in cancer research. Flat cell cultures often lose phenotypic heterogeneity over time and lack the stromal and immune context necessary for authentic tumor modeling. Animal models, while invaluable, suffer from species differences that can skew therapeutic outcomes and are constrained by ethical and financial considerations. PDOs circumvent many of these challenges by capturing patient-specific tumor features ex vivo, enabling real-time functional assays that are both scalable and more reflective of patient biology.

One of the most striking advantages of PDOs lies in their application for high-throughput drug screening. By generating biobanks of organoids from diverse tumor types, including colorectal, gastric, pulmonary, and breast cancers, researchers can rapidly assay the efficacy of chemotherapeutics, targeted agents, and immunotherapies. This approach has shown compelling concordance with clinical responses, offering a predictive platform that personalizes therapy selection and expedites the identification of effective treatment combinations.

Moreover, PDOs facilitate the study of tumor-immune interactions through sophisticated co-culture systems with stromal and immune cells. These integrated models provide a novel in vitro avenue to evaluate the mechanisms underlying immune evasion and response to immunotherapies such as checkpoint inhibitors and chimeric antigen receptor T-cell (CAR-T) therapies. The ability to simulate the tumor microenvironment (TME) in 3D cultures marks a pivotal step in understanding cancer immunology, enabling researchers to decipher resistance pathways and optimize immunotherapeutic strategies.

Technological innovations are amplifying the scope and depth of organoid research. The advent of microfluidic “organoid-on-a-chip” platforms introduces dynamic environmental controls, enabling the modeling of processes like metastasis, angiogenesis, and drug pharmacokinetics with unprecedented precision. When combined with cutting-edge single-cell RNA sequencing and mass spectrometry-based proteomics, these tools unravel the molecular heterogeneity and signaling networks within tumors, revealing novel biomarkers and therapeutic targets previously obscured in bulk analyses.

Crucially, PDOs are proving instrumental in accelerating cancer vaccine development. By preserving patient-specific neoantigens and simulating immune response ex vivo, organoid models allow for the screening and validation of vaccine candidates tailored to the tumor’s antigenic landscape. This innovative approach portends a future where personalized cancer vaccines can be designed rapidly and tested efficiently, ushering in a paradigm shift in immunoprevention and therapy.

Despite their immense promise, PDO systems are not without challenges. The cultivation process remains resource-intensive, requiring specialized expertise and infrastructure. Furthermore, the absence of vascularization and the incomplete integration of immune components limit the full replication of tumor physiology over extended culture periods. Addressing these limitations demands ongoing refinement of co-culture protocols and bioengineering approaches to incorporate vasculature and more comprehensive immune cell repertoires, ultimately enhancing the translational relevance of organoids.

The translational impact of organoid technology reverberates beyond laboratory research. Clinicians increasingly utilize PDO-guided drug response profiles to tailor therapies, minimizing exposure to ineffective regimens and associated toxicities. This clinically actionable insight into tumor behavior elevates individualized care and informs real-time adjustments in treatment plans. Concurrently, pharmaceutical development benefits from organoid platforms by streamlining preclinical drug testing, reducing costs, and decreasing reliance on animal models while enhancing predictive validity.

Underpinning this paradigm shift, a recent comprehensive review by scientists at Peking University People’s Hospital synthesizes the current landscape of organoid research in cancer modeling and therapeutic discovery. Published in the journal Cancer Biology & Medicine, their analysis elucidates the functional attributes of patient-derived organoids, their applications in drug testing and immunotherapy, and the persisting challenges impeding broader clinical adoption. The review highlights the integrative potential of combining organoids with multi-omics and microengineering technologies as the vanguard of precision oncology innovation.

As research continues to refine and expand the organoid toolkit, the vision of modeling human cancer as a living, patient-specific ecosystem becomes increasingly tangible. PDOs are poised to revolutionize how therapies are developed, validated, and personalized, narrowing the translational gap that has long hindered progress. The convergence of patient-derived models with advanced analytical technologies charts a pathway toward predictive, efficient, and bespoke cancer care that holds transformative promise not only for patients but for the entire oncology research community.

In the words of Dr. Kezhong Chen, senior author of the review, “Organoids have transformed the way we approach cancer research. They allow us to study tumors as living ecosystems, capturing both genetic complexity and immune dynamics. This means we can test therapies in conditions far closer to reality and predict how individual patients might respond. The potential is immense—not only for refining today’s treatments but also for developing tomorrow’s personalized cancer vaccines.” This powerful testament underscores the revolutionary impact organoids wield in shaping the future of cancer medicine, bridging the divide between bench and bedside with unprecedented fidelity.

The integration of organoid technology into the continuum of cancer research and clinical practice heralds a new chapter in the fight against cancer. From enabling mechanistic dissection of tumor biology to facilitating tailored therapeutic discovery and vaccine development, organoids serve as a versatile, high-fidelity platform. Though hurdles remain in standardization, scalability, and long-term culture stability, ongoing innovations in bioengineering and co-culture methodologies promise to surmount these barriers. Ultimately, patient-derived tumor organoids stand as a beacon of hope in oncology, advancing the cause of personalized medicine and translating scientific insight into tangible patient benefit.

Subject of Research: Cancer modeling and therapeutic discovery using patient-derived tumor organoids

Article Title: Functional characteristics, applications, and limitations of patient-derived tumor organoids in cancer modeling and therapeutic discovery

News Publication Date: 24-Jul-2025

Web References:
http://dx.doi.org/10.20892/j.issn.2095-3941.2025.0127

References:
DOI: 10.20892/j.issn.2095-3941.2025.0127

Image Credits: Cancer Biology & Medicine

Keywords: Organoids, tumor microenvironment, cancer modeling, precision oncology, immunotherapy, drug screening, tumor heterogeneity, patient-derived models, organoid-on-a-chip, cancer vaccines, single-cell sequencing, proteomics